Page last updated: 2024-12-06

cholesteryl succinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cholesteryl succinate is an ester formed from cholesterol and succinic acid. It has been studied for its potential applications in various fields, including drug delivery, biomaterials, and nanotechnology. Its synthesis typically involves reacting cholesterol with succinic anhydride under suitable conditions. Cholesteryl succinate exhibits interesting properties, such as its ability to form self-assembled structures and its potential for controlled release of various drugs. Its biocompatibility and potential for targeted delivery have made it an attractive candidate for drug delivery systems. Additionally, its liquid crystalline properties have led to its exploration as a component in biomaterials and as a building block for nanostructures.'

cholesteryl succinate: RN given refers to (3beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cholesteryl hemisuccinate : A dicarboxylic acid monoester resulting from the formal condensation of the hydroxy group of cholesterol with one of the carboxy groups of succinic acid. A detergent that is often used to replace cholesterol in protein crystallography, biochemical studies of proteins, and pharmacology. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65082
CHEBI ID138742
SCHEMBL ID330610
MeSH IDM0061219

Synonyms (41)

Synonym
AKOS015839518
cholesterol hemisuccinate
1510-21-0
cholesteryl hemisuccinate
cholesteryl succinate
CHEBI:138742
4-[[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid
3beta-hydroxy-5-cholestene 3-hemisuccinate
4-[(3beta)-cholest-5-en-3-yloxy]-4-oxobutanoic acid
cholest-5-en-3beta-yl hydrogen succinate
cholesterol hydrogen succinate
succinic acid monocholesterol ester
y01 ,
t3j4ks4201 ,
unii-t3j4ks4201
nsc 628321
einecs 216-148-6
chems
SCHEMBL330610
cholesterylhemisuccinate
cholest-5-en-3-ol (3.beta.)-, hydrogen butanedioate
3-cholesteryloxycarbonylpropanoic acid
succinic acid monocholesteryl ester
cholesteryl succinate [inci]
cholest-5-en-3-ol (3.beta.)-, 3-(hydrogen butanedioate)
monocholesteryl succinate
3-(3-cholesteryloxycarbonyl)propionic acid
cholesterol, hydrogen succinate
W-108066
3.beta.-(3-carboxypropanoyloxy)cholest-5-ene
5-cholesten-3.beta.-ol hydrogen succinate
E10155
AS-46683
DTXSID10934145
4-[(cholest-5-en-3-yl)oxy]-4-oxobutanoic acid
cholest-5-en-3-ol (3beta)-, 3-(hydrogen butanedioate)
CS-W011516
Q27289619
3-(3-cholesteryloxycarbonyl)propanoic acid3beta-hydroxy-5-cholestene 3-hemisuccinate; 5-cholesten-3beta-ol 3-hemisuccinate; cholesteryl hydrogen succinate
A884121
BP-29634

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical."( Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.
Fariss, MW; Lippman, HR; Mumaw, VR; Ray, SD, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
"Delivery activity of pH-sensitive 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE):cholesteryl hemisuccinate (CHEMS) liposomes was assessed as an in vitro intracellular carrier system to increase the bioavailability of depigmentation actives."( Enhanced depigmenting effects of N-glycosylation inhibitors delivered by pH-sensitive liposomes into HM3KO melanoma cells.
Chang, IS; Choi, H; Hwang, JS; Kim, J; Park, JY,
)
0.13
" Pharmacokinetic assessments showed advantages of systemic bioavailability of FTL-UA (AUC = 218."( In vitro and in vivo antitumor effects of folate-targeted ursolic acid stealth liposome.
Lu, M; Ma, X; Xiang, G; Yang, G; Yang, T; Zhang, W, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" In dose-response studies, down-regulation of the receptor by 58-035 paralleled its inhibition of ACAT activity."( Inhibition of acyl coenzyme A:cholesterol acyl transferase in J774 macrophages enhances down-regulation of the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase and prevents low density lipoprotein-induced cholesterol ac
Tabas, I; Tall, AR; Weiland, DA, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
detergentA surfactant (or a mixture containing one or more surfactants) having cleaning properties in dilute solutions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
cholestane esterAny steroid ester based on a cholestane skeleton.
dicarboxylic acid monoesterA monoester of a dicarboxylic acid.
hemisuccinateA succinate ester in which only one of the carboxy groups of succinic acid has been esterified.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (162)

TimeframeStudies, This Drug (%)All Drugs %
pre-199044 (27.16)18.7374
1990's39 (24.07)18.2507
2000's29 (17.90)29.6817
2010's44 (27.16)24.3611
2020's6 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.65 (24.57)
Research Supply Index5.15 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.18%)5.53%
Reviews2 (1.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other165 (97.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]